ASH 2013: Dr. Adrian Wiestner Discusses Progno... - CLL Support

CLL Support

22,986 members39,473 posts

ASH 2013: Dr. Adrian Wiestner Discusses Prognostic and Predictive Factors, the Nuances of 17p deletion and Residual Disease

bkoffman profile image
bkoffmanCLL CURE Hero
1 Reply

Friends,

In my blog bkoffman.blogspot.com I have posted the second part of Dr. Wiestner's interview that addresses some of the subtleties of CLL that we are gradually beginning to understand from the research begin done by his team at the NIH and others around the world.

We are moving the needle, but it is still not pointing at cure.

Stay strong. Merry Christmas.

Brian

Written by
bkoffman profile image
bkoffman
CLL CURE Hero
To view profiles and participate in discussions please or .
1 Reply
jangreen profile image
jangreen

Hi I think a lot of important issues are raised in this interview.One about long term. But no one has a crystal ball. Best wishes

Not what you're looking for?

You may also like...

ASH 2014. Dr. Sharman discusses the biology of our CLL cells

Friends, This week on the CLL Society website http://cllsociety.org, we share the first part of an...

"there has been a further reduction in the presence of the disease and limited evidence of any residual disease"

So said my consultant this week! 6 cycles of FCR totally worth it to get this news. No more blood...

ASH 2018: Dr. Chadi Nabhan on the Cost of Ibrutinib vs. Chemo vs Chemoimmunotherapy in CLL and on way too much chemo being used.

Hi, If you have been on our website recently you have already met Dr. Nabhan talking about patient...

ASH 2013: Dr. John Pagel Speculates on the Future of CLL Therapies including the late breaking data on Idelalisib

ASH 2013: Dr. John Pagel Speculates on the Future of CLL (chronic lymphocytic leukemia) Therapies...

Covid and Life after 12 Weeks of Medical Isolation

So we are now 3 weeks into our 12 weeks of lockdown, what about life for us once the restrictions...